A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease

Acta Neurologica Scandinavica

Volumn 121, Issue 4, 2010, Pages 217-224

  Narasimhalu, K ^a,b   Effendy, S ^c   Sim, C H ^c   Lee, J M ^c   Chen, I ^c   Hia, S B ^c   Xue, H L ^d   Corrales, M P ^c   Chang, H M ^c   Wong, M C ^e   Chen, C P ^a   Tan, E K ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d ICM Pharma Pte Ltd   (Singapore)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cognitive impairment no dementia; Rivastigmine; Stroke

Indexed keywords

PLACEBO; RIVASTIGMINE;

ACCIDENT; ADULT; AGED; ANOREXIA; ARTICLE; BLURRED VISION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; FOOT FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VERBAL BEHAVIOR; VOMITING; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYLCARBAMATES; PILOT PROJECTS; STROKE; TREATMENT OUTCOME;

EID: 77749279917     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01263.x     Document Type: Article

References (26)

1. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008 148 : 379 397.
2. Birks J, Flicker L. Investigational treatment for vascular cognitive impairment. Expert Opin Investig Drugs 2007 16 : 647 658.
3. O'brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol 2003 2 : 89 98.
4. Tuokko H, Frerichs R, Graham J et al. Five-year follow-up of cognitive impairment with no dementia. Aging Ment Health 2003 60 : 577 582.
5. Rockwood K, Wentzel C, Hachinski V, Hogan DB, Macknight C, Mcdowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular cognitive impairment investigators of the Canadian Study of Health and Aging. Neurology 2000 54 : 447 451.
6. Yeo D, Gabriel C, Chen C, Lee S, Loenneker T, Wong M. Pilot validation of a customized neuropsychological battery in elderly Singaporeans. Neurol J Southeast Asia 1997 2 : 123.
7. Association AP. Diagnostic and statistical manual of mental disorders - IV. Washington, DC : American Psychiatric Association, 1994.
8. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
9. Manos PJ, Wu R. The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med 1994 24 : 229 244.
10. D'elia LS P, Uchiyama CL, White T. Color Trails Test, Lutz, FL : Psychological Assessment Resources Inc, 1996.
11. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988 24 : 627 628.
12. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000 55 : 1621 1626.
13. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997 11 (Suppl. 2 S33 9.
14. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 44 : 2308 2314.
15. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982 17 : 37 49.
16. StataCorp. Stata. College Station, TX : StataCorp, 2005.
17. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY) 2005 1 : 40 5.
18. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 1999 6 : 423 429.
19. Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005 19 : 51 6.
20. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartare), a new acetylcholinesterase inhibitor, in patients with mile to moderate Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 : 55 65.
21. Potkin SG, Anand R, Fleming K et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 2001 4 : 223 230.
22. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 318 : 633 638.
23. Ballard C, Margallo-Lana M, Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005 330 : 874.
24. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007 6 : 782 792.
25. Dichgans M, Markus HS, Salloway S et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008 7 : 310 318.
26. Chen Y, Shohami E, Constantini S, Weinstock M. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. J Neurotrauma 1998 15 : 231 237.